Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry.

[1]  F. Germini,et al.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. , 2015, Chest.

[2]  Lara A. Kahale,et al.  Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2014, The Cochrane database of systematic reviews.

[3]  K. Bailey,et al.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. , 2014, Blood.

[4]  G. Raskob,et al.  O R I G I N a L C L I N I C a L I N V E S T I G a T I O N Open Access , 2022 .

[5]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[6]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[7]  K. Bailey,et al.  Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. , 2011, Blood.

[8]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[9]  M. Monreal,et al.  Bleeding complications associated with anticoagulant therapy in patients with cancer. , 2010, Thrombosis research.

[10]  N. Dowling,et al.  Periprocedural Anticoagulation Management of Patients With Venous Thromboembolism , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[11]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[12]  Russell D Hull,et al.  Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. , 2006, The American journal of medicine.

[13]  Jawed Fareed,et al.  Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[14]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[15]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[16]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[17]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[18]  R J Prineas,et al.  International diagnostic criteria for acute myocardial infarction and acute stroke. , 1984, American heart journal.

[19]  K. Wołkowska.  Summary of the article: Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous tromboemolism. N Engl J Med, 2010; 363: 2499-2510 , 2011 .